glp-1 vermont Cutting coverage may cost UVM Health more than it saves The University of Vermont Health
Description
Five clinical trials in type 2-diabetic subjects (SURPASS 15) have shown that tirzepatide at 515 mg per week reduces both HbA1c (1.24 to 2.58%) and body weight (5.411.7 kg) by amounts unprecedented for a single agent
Includes medication, clinician care, 1:1 coaching & Noom Weight program

[For more on that, you can read my post serving up more of that context and controversy]

This product should not be taken by those who are pregnant or nursing
